Cryoablation’s Superior Safety Profiled at Major Cardiology Conference
Supports use of Cryoenergy in AF, VT and SVT Markets
Anaheim, California, USA - October 13, 2001 - American Heart Association Conference - Two leading cardiology research centers presented technical abstracts yesterday detailing the advantages of cryoenergy over radiofrequency-based (RF) treatments in reducing both thrombogenicity (clot formation) and the risk of coronary artery stenosis (closing or narrowing of the vessel lumen) when treating cardiac arrhythmias. These two animal studies from The Montreal Heart Institute (represented at the conference by Patrick Chauvet of CryoCath Technologies) and The University of Oklahoma Health Sciences Center, used FreezorTM technology from CryoCath Technologies, the world leader in cryotherapy products to treat cardiovascular disease, to generate their findings.
Cryoenergy’s superior safety profile (reduced thrombosis, stenosis and collateral damage) opens the door for more aggressive ablation particularly on the left side of the heart where 75% of all arrhythmias originate. Dr. Dubuc’s study demonstrated that cryoenergy reduces the risk of producing a clotting event, which can cause severe complications, including stroke.
CryoCath’s growth strategy has seen the Company work closely with cardiology opinion leaders around the world as it seeks to demonstrate the significant human and financial benefits of cryotechnology. CryoCath conducted a highly successful launch in Europe during 2001; many leading European cardiology centers now use Freezor technology. As the Company prepares to enter the North American market upon regulatory approval, it intends to leverage the experience gained in Europe into successful Canadian and U.S. launches in 2002 and 2003 respectively. CryoCath expects to complete its pivotal U.S. IDE study by Q1, 2002, with enrolment now more than 50% complete.
About Medtronic CryoCath
CryoCath is a medical technology company that leads the world in creating minimally invasive, catheter-based cryotherapy products to treat cardiovascular disease across three broad indications: tachyarrhythmia (CryoCath’s primary focus), ischemia and restenosis. CryoCath has already successfully launched its first product, the Freezor CryoAblation System, in Europe and is developing additional products to expand its pipeline of products to treat tachyarrhythmia. As well, it is also involved in the co-development and commercialization of the SurgiFrostTM cryosurgical probe to treat AF. CryoCath expects to achieve U.S. commercialization in 2002 and for Freezor in 2003.
Medtronic CryoCath Products
For further information, please contact: